Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franz-Werner Haas</td>
<td>Business Update</td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td></td>
</tr>
<tr>
<td>Ulrike Gnad-Vogt</td>
<td>Clinical Update</td>
</tr>
<tr>
<td>Interim Chief Development Officer</td>
<td></td>
</tr>
<tr>
<td>Pierre Kemula</td>
<td>Financial Update</td>
</tr>
<tr>
<td>Chief Financial Officer</td>
<td></td>
</tr>
<tr>
<td>Mariola Fotin-Mleczek</td>
<td>Q&amp;A Availability</td>
</tr>
<tr>
<td>Chief Technology Officer</td>
<td></td>
</tr>
</tbody>
</table>
Selected Key Highlights

**Clinical Developments**

**CVnCoV: COVID-19 vaccine candidate**
- Pivotal Phase 2b/3:
  - Fully recruited with over 40,000 participants
  - Amendment submitted to address virus variants
  - Interim analysis for vaccine efficacy exp. Q2 2021
- Phase 2a amendment for vaccine efficacy submitted
- Expanding COVID-19 vaccine program:
  - Three new Phase 3 trials to be initiated shortly
  - Phase 2a expansion for adolescents
- CVnCoV protection demonstrated against South African variant in preclinical challenge study

**CV8102: Cancer immuno-modulator in solid tumors**
- Phase 1 expansion cohort initiated in advanced melanoma
- Preferred dose of 600µg selected for anticipated Phase 2

**COVID-19 Program Partnerships**
- Bayer collaboration: 1st generation COVID-19 vaccines
- GSK collaboration: 2nd generation COVID-19 vaccines
- UK Government: variant expertise and scientific input*

**CVnCoV Manufacturing**
- Adding partners for broad manufacturing network
- Increasing 2022 capacity guidance to up to 1bn
- Reaffirming 2021 capacity guidance of up to 300m

**Financial results**
- Capital raise: gross proceeds of $517.5 million
- Cash position of €1.32 billion as of Dec 31st, 2020

*Subject to ongoing negotiations*
2020 – Year of Corporate Transformation

Growing talent base:
>500 employees

Growing a commercial organization

Expanding Management expertise

Manufacturing scaling-up

EC supply agreement

Accelerated clinical development

Rigorous pre-clinical candidate selection

Strategic partnerships

Strong cash position with €1.32 billion*

2020
Year of Corporate Transformation

CureVac │ Fourth Quarter and Full-Year 2020 Results

*As of December 31, 2020

EC: European Commission

CVAC
Nasdaq Listed

Well financed to drive business transformation
2020 – Propelling CureVac Forward

Building a **commercial** organization

Preparing first **product launch**

Anticipating 2021 **revenue** generation*

Unique mRNA **technology**

Strong **science** expertise

High operational **agility**

*The forecast is prepared by the Company’s management using its best estimate and judgment based on past experience and actual knowledge and progress of the Company’s performance as of the date of this presentation, and have been based on several assumptions, many of which are outside the influence of the Company’s management. Any deviation of certain of these assumptions could materially change the outcome of the forecast.
Our Core Mandate 2021: Deliver a Safe and Effective COVID-19 Vaccine

**Succeeding in the clinic**
- Expect to provide first efficacy data in Q2 2021
- Expect to apply for regulatory approval in Q2 2021

**Creating capacity**
- 3 in-house GMP certified suites
- 4th large-scale suite in progress
- Broad and integrated European CDMO network

**Delivering the vaccine**
- Bayer adding key operational and commercial support
- GSK adding expertise for joint development of 2nd-generation COVID-19 vaccines
## CureVac Pipeline: A Diversified Portfolio

<table>
<thead>
<tr>
<th>AREA</th>
<th>PROGRAMS AND INDICATIONS</th>
<th>COLLABORATIONS</th>
<th>PRE-CLINICAL DISCOVERY</th>
<th>PRE-CLINICAL DEVELOPMENT</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PROPHYLACTIC VACCINES</strong></td>
<td>CVnCoV: COVID-19</td>
<td>CEPI (2)</td>
<td></td>
<td></td>
<td>(1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COVID-19 2nd-generation vaccines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV7202: Rabies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lassa, Yellow Fever</td>
<td>CEPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respirational Syncytial Virus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other Infectious Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diverse projects (Rota, Malaria, Universal Influenza)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ONCOLOGY</strong></td>
<td>CV8102: cMEL, ACC, SCC, HNSCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BI13618409 (CV9202): Non-Small Cell Lung Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shared neo-antigen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumor Associated Antigens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROTEIN THERAPY</strong></td>
<td>Cas9 Gene-editing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ocular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung Respiratory Diseases</td>
<td>Yale</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapeutic Antibodies</td>
<td>Genmab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. We have initiated a combined Phase 2b/3 clinical trial for CVnCoV
2. CEPI early stage Phase 1 clinical trial funding

**Abbreviations:**
- cMEL: Cutaneous melanoma; ACC: Adenoid cystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck
## Rapidly Expanding the COVID-19 Vaccine Program

### COVID-19 Program: CVnCoV

<table>
<thead>
<tr>
<th>TRIAL NO.</th>
<th>CLINICAL STUDY</th>
<th>LOCATION</th>
<th>OBJECTIVE</th>
<th>STUDY SIZE</th>
<th>STATUS</th>
<th>DOSE</th>
<th>EXP. DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>001</td>
<td>Phase 1</td>
<td>Germany</td>
<td>Dose-escalation</td>
<td>280</td>
<td>Fully recruited</td>
<td>2-20 µg</td>
<td>Publication submitted</td>
</tr>
<tr>
<td>002</td>
<td>Phase 2a</td>
<td>Peru</td>
<td>Dose-confirmation</td>
<td>674</td>
<td>Fully recruited</td>
<td>6 µg / 12 µg</td>
<td>Q2/2021</td>
</tr>
<tr>
<td>002 NEW</td>
<td>Phase 2a amendment</td>
<td>Peru</td>
<td>Adolescents (12 to 17)</td>
<td>40 (initial cohort)</td>
<td>Amendment submitted</td>
<td>6 µg / 12 µg</td>
<td></td>
</tr>
<tr>
<td>005</td>
<td>Phase 3</td>
<td>Germany (Mainz)</td>
<td>Healthcare population</td>
<td>2,500</td>
<td>&gt;90% recruited</td>
<td>12 µg</td>
<td>Q2/2021</td>
</tr>
<tr>
<td>003 NEW</td>
<td>Phase 3</td>
<td>Belgium</td>
<td>Participants with co-morbidities</td>
<td>1,200</td>
<td>Starting shortly</td>
<td>12 µg</td>
<td></td>
</tr>
<tr>
<td>011 NEW</td>
<td>Phase 3</td>
<td>Argentina, Colombia, Peru</td>
<td>Co-administration with flu vaccine</td>
<td>1,000</td>
<td>Starting shortly</td>
<td>12 µg</td>
<td></td>
</tr>
<tr>
<td>012 NEW</td>
<td>Phase 2</td>
<td>France</td>
<td>Age comparison (18-45 vs. ≥65)</td>
<td>180</td>
<td>Starting shortly</td>
<td>12 µg</td>
<td></td>
</tr>
</tbody>
</table>

| UK Government Vaccine Task Force* | - | CVnCoV variant optimized | - | Expected start in Q3/2021 | - | - |
| GSK partnership | - | 2nd generation COVID-19 vaccine | - | Expected start in Q3/2021 | - | - |

---

*Subject to ongoing negotiations*
Variants of Concern Spreading in Phase 2b/3 Trial Geographies

UK strain (B.1.1.7 / 501Y.V1)

SA strain (B.1.351, 501Y.V2)

Brazil strain (P.1, 501Y.V3)

Other incl. original strain

**UK** strain

**SA** strain

**Brazil** strain

**Other** incl. original strain

*SOUTH AMERICA*

*As of April 13, source: www.nextstrain.org / South America- or Europe-focused sub-sampling*

SA: South Africa

EUROPE

Countries where Phase 2b/3 trial is conducted
Adjusting Late-Stage CVnCoV Trials to the Dynamics of the Virus

PHASE 2b/3
- Fully enrolled
- Over 40,000 participants
- 1:1 randomization

ADDRESSING VARIANTS OF CONCERN
- Secondary endpoint added addressing variants
- Specifying variant-dependent efficacy readout
- Original and UK strain for additional analysis

PHASE 2a
- Fully enrolled
- ~270 participants aged over 60 vaccinated
- 10:1 randomization

UTILIZING HIGH COVID-19 PREVALENCE
- Harness potential of high COVID-19 case numbers
- Include secondary endpoint for efficacy
- Data focus on important group of older adults
Evidence of Protection Against South Africa Strain in Preclinical Study

Variant of Concern
B.1.351 (SA strain)

Original strain
BavPat1

Efficient protection from **challenge with B.1.351** by vaccination with 8µg of CVnCoV

<table>
<thead>
<tr>
<th>Survival non-vaccinated</th>
<th>Survival CVnCoV vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>BavPat1</td>
<td>20%</td>
</tr>
<tr>
<td>B.1.351</td>
<td>0%</td>
</tr>
</tbody>
</table>

- Vaccinated animals were protected from disease and mortality

- Robust induction of antibody titers for BavPat1, **significantly lower** antibody titers for B.1.351

**LOWER RESPIRATORY TRACT: TRACHEA, LUNGS**

- **Full protection**, no B.1.351 detectable

**CENTRAL NERVOUS SYSTEM: BRAIN**

- **Full protection**, no B.1.351 detectable

**UPPER RESPIRATORY TRACT: CONCHAE**

- Residual viral load
  - no statistical significance

*Full manuscript of pre-clinical data available on bioRxiv pre-print server*
Expanding European Manufacturing Network with Experienced Partners

Manufacturing partners

- WACKER
- gsk GlaxoSmithKline
- BAYER
- Rentschler Biopharma
- NOVARTIS
- CELONIC
- FAREVA

2021
- mRNA production
- mRNA formulation
- Fill & Finish

Up to 300 million doses

2022
- Packaging

Up to 1 billion doses

CureVac │ Fourth Quarter and Full-Year 2020 Results
The RNA Printer®, Decentralized Mobile mRNA Production

RNA Printer® 2.0

pDNA production

mRNA production

PANDEMIC PREPAREDNESS
in hospitals in outbreak regions

CUSTOMIZED, POINT OF CARE
mRNA vaccines and therapeutics

CLINICAL DEVELOPMENT
acceleration at lower costs
Solid Foundation for Sustainable Value Creation

Operational expertise

World Class Variant Vaccines Expert Advisory Group

Vaccine development expertise

Execution power

Scientific expertise

Combination vaccines

International reach

International reach

First-generation COVID-19 vaccines, CVnCoV
Collaboration and Services Agreement

Variant epidemiology, genomics and surveillance
R&D collaboration*

Second-generation COVID-19 vaccines
Co-Development Partnership

*Subject to ongoing negotiations
Capital Inflow Fuels Corporate Transformation

+4,210%

Full-year 2019
- Collaboration & upfront payments: €30,7m
- Grants: €579m
- Finance rounds & equity: €120m
- Loan: €874m
- Personnel expenses: €50m
- 3rd Party related cash-out: €35m
- Other: €200m
- Full-year 2020: €1.32bn

+4,210%
Follow-On Financing: Securing Additional Funds to Grow the Business

$517.5 million
Aggregated gross proceeds

€1.32bn
Cash position as of December 31, 2020

5,000,000
New common shares issued

750,000
Full option exercised for additional shares

IPO Follow-On
Feb 2021
# Cash and Condensed Consolidated P&L Statement

## Year ended December 31,

<table>
<thead>
<tr>
<th>(in € millions)</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>1,322.6</td>
<td>30.7</td>
</tr>
</tbody>
</table>

## Three Month ended December 31,

<table>
<thead>
<tr>
<th>(in € millions)</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>48.9</td>
<td>17.4</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>-158.7</td>
<td>-116.9</td>
</tr>
<tr>
<td>Operating Result</td>
<td>-109.8</td>
<td>-99.5</td>
</tr>
<tr>
<td>Financial Result</td>
<td>-20.0</td>
<td>-0.6</td>
</tr>
<tr>
<td><em>Earnings before Taxes (EBT)</em></td>
<td>-129.8</td>
<td>-100.1</td>
</tr>
</tbody>
</table>
A year of fundamental corporate transformation further advances development from Biotech to a commercial Biopharma company

CureVac’s COVID-19 lead candidate, CVnCoV, in final stage of clinical development and well on track for conditional approval

Positioned for sustained value creation in the pandemic and beyond with strong partners, first- and second-generation vaccines and oncology pipeline

Expanding European manufacturing network with highly experienced partners for capacity ramp-up and updated 2022 guidance

Nasdaq listing and favorable cash position of €1.32 billion*
Thank you for your attention